other material
confidence high
sentiment negative
materiality 0.85
Bionano Genomics, Inc. (BNGO): restructuring charge — Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction
Bionano Genomics, Inc.
- Q4 2023 revenue $10.7M, FY 2023 revenue $36.1M, both up 30% YoY.
- GAAP gross margin Q4 23%, FY 26% (up from 21% in 2022).
- Plans to cut 110-125 employees (34-39% of workforce) and phase out testing services generating 19.4% of FY 2023 revenue.
- Restructuring expected to yield $35-40M annual operating expense savings starting H2 2024.
- No specific 2024 revenue guidance provided; cash and securities $102.3M at year-end.